Keros Therapeutics, Inc. (KROS) has 57 open-market insider trades by 18 insiders since 2020. Over the last six months insiders net sold $95K. The most active filer is Julius Knowles, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Daniel Schneeberger | 10% Owner | — | 1 | $191.3M | 2025-10-15 |
| Pontifax (China) IV L.P. | Dir10% Owner | — | 1 | $107.6M | 2025-10-15 |
| Julius Knowles | Dir | — | 18 | $26.4M | 2026-06-04 |
| Carl L. Gordon | Dir | — | 2 | $17.0M | 2025-11-21 |
| ADAR1 Partners, LP | 10% Owner | — | 1 | $10.2M | 2025-04-09 |
| Ran Nussbaum | Dir10% Owner | — | 1 | $7.0M | 2025-06-04 |
| Tomer Kariv | Dir10% Owner | — | 1 | $7.0M | 2025-06-04 |
| Jennifer Lachey | CSO | — | 17 | $5.8M | 2022-07-15 |
| Keith Regnante | CFO | — | 3 | $3.7M | 2026-02-18 |
| Pontifax (Israel) IV, L.P. | Dir10% Owner | — | 1 | $3.0M | 2020-11-17 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Esther Cho | CLO | Sell | $46K | 2026-08-18 |
| Charles W. Newton | Director | Sell | $6K | 2026-08-18 |
| Lorena Raquel Lerner | CSO | Sell | $37K | 2026-08-18 |
| Annita Tanini | VP & Controller | Sell | $13K | 2026-08-18 |
| Jean Jacques Bienaime | Director | Buy | $10K | 2026-08-17 |
| Jean Jacques Bienaime | Director | Buy | $11K | 2026-07-15 |
Companies that share insiders with KROS, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Jean Jacques Bienaime | Director | Buy | $10K | 2026-06-15 |
| Charles W. Newton | Director | Sell | $6K | 2026-06-11 |
| Julius Knowles | Director | Sell | $28K | 2026-06-04 |
| Alpna Seth | Director | Sell | $28K | 2026-06-04 |
| Jean Jacques Bienaime | Director | Buy | $11K | 2026-05-15 |
| Jean Jacques Bienaime | Director | Buy | $12K | 2026-04-15 |
| Jean Jacques Bienaime | Director | Buy | $22K | 2026-03-09 |
| Jasbir Seehra | CEO | Sell | $113K | 2026-02-19 |
| Esther Cho | SVP & General Counsel | Sell | $78K | 2026-02-18 |